Literature DB >> 9822281

Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

S Demotz1, W Ammerlaan, P Fournier, C P Muller, C Barbey.   

Abstract

MHC class II molecules present to CD4+ T cells protein fragments which mostly derive from the extracellular and from the endosomal compartments. Determinants of cytosolic proteins are, however, also displayed by MHC class II molecules following pathways which are still not yet fully characterized. Here we describe the isolation of DRB1*1103-restricted T cell clones specific for the measles virus (MV) nucleoprotein peptide 185-199 (N185). Experiments were then conducted to delineate how this determinant is assembled with DR molecules. In vitro binding analyses indicated that complexes between the N185 peptide and DRB1*1103 protein are optimally constituted at pH 4-4.5. In cellular experiments it was observed that chloroquine, leupeptin and emetine, which are classical inhibitors of presentation of MHC class II-restricted antigens, when added during infection of B cells with MV, prevent presentation of the N185 determinant. In addition, it was found that the N185 determinant is efficiently presented when the nucleoprotein is exogenously provided to B cells, either by blocking MV fusion with the peptide FFG or by the use of purified nucleoprotein. In contrast, it was observed that nucleoprotein recombinant vaccinia virus (vv-N)-infected B cells weakly stimulated N185-specific T cells, indicating that the restricted localization of the nucleoprotein in the cytosol resulted in a poor presentation of the N185 determinant. Taken together, these findings suggest that it is prior to delivery of the nucleoprotein into the cytosol that the N185 determinant is efficiently assembled with newly synthesized DR molecules in the acidic environment of the endosomal compartment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822281      PMCID: PMC1905115          DOI: 10.1046/j.1365-2249.1998.00716.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

2.  Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.

Authors:  P A Roche; M S Marks; P Cresswell
Journal:  Nature       Date:  1991-12-05       Impact factor: 49.962

3.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells.

Authors:  S Jacobson; R P Sekaly; C L Jacobson; H F McFarland; E O Long
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

4.  Delineation of several DR-restricted tetanus toxin T cell epitopes.

Authors:  S Demotz; A Lanzavecchia; U Eisel; H Niemann; C Widmann; G Corradin
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

5.  Intracellular assembly and transport of endogenous peptide-MHC class II complexes.

Authors:  A Y Rudensky; M Maric; S Eastman; L Shoemaker; P C DeRoos; J S Blum
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

6.  Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes.

Authors:  S Amigorena; J R Drake; P Webster; I Mellman
Journal:  Nature       Date:  1994-05-12       Impact factor: 49.962

7.  Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.

Authors:  A Oxenius; M F Bachmann; P G Ashton-Rickardt; S Tonegawa; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1995-12       Impact factor: 5.532

8.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Authors:  R M Chicz; R G Urban; J C Gorga; D A Vignali; W S Lane; J L Strominger
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

9.  Membrane interactions influence the peptide binding behavior of DR1.

Authors:  M A Sherman; H A Runnels; J C Moore; L J Stern; P E Jensen
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells.

Authors:  D Jaraquemada; M Marti; E O Long
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  4 in total

1.  Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides.

Authors:  Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Vaccine       Date:  2006-05-03       Impact factor: 3.641

2.  Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Authors:  Michael N Ha; Sébastien Delpeut; Ryan S Noyce; Gary Sisson; Karen M Black; Liang-Tzung Lin; Darius Bilimoria; Richard K Plemper; Gilbert G Privé; Christopher D Richardson
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

3.  HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: a pilot study.

Authors:  David M Phelan; Gregory A Poland
Journal:  Vaccine       Date:  2012-08-31       Impact factor: 3.641

Review 4.  The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.

Authors:  Maja Šantak; Zrinka Matić
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.